Abatacept now approved for rheumatoid arthritis after failure of conventional DMARDs

Following a review, NICE have overturned their previous negative decision for abatacept (Orencia) following the introduction of a patient access scheme.

This new guidance brings the drug in line with other anti-TNF drugs licensed for the treatment of rheumatoid arthritis (pictured) that have been approved by NICE for NHS use | SCIENCE PHOTO LIBRARY

Previously, abatacept was only approved for use in rheumatoid arthritis after the failure of a TNF inhibitor. Now it may also be used in adults whose disease has responded inadequately to 2 conventional disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate, provided the manufacturer supplies abatacept with the discount agreed in the patient access scheme.

View Orencia drug record

NICE guidance on abatacept in rheumatoid arthritis after failure of conventional DMARDS

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Back of man's head suffering from alopecia

Alopecia drug to be available on the NHS

In an NHS first, NICE is recommending ritlecitinib...

Stressed male GP with hand on head